NJ S 4222
in committeeImproves access to lower-cost generic and biosimilar drugs.
New Jersey · 222 · upper
Quick answers
Did NJ S 4222 pass?
Not yet. NJ S 4222 is in committee as of 2026-05-14 and has not come to a final vote. Latest recorded action (2026-05-14): Introduced in the Senate, Referred to Senate Commerce Committee
What is NJ S 4222 about?
NJ S 4222 is a bill in the 222 titled “Improves access to lower-cost generic and biosimilar drugs.”.
Who sponsors NJ S 4222?
Johnson, Gordon M. is the primary sponsor of NJ S 4222.
- Introduced
- 2026-05-14
- Latest action
- 2026-05-14 — Introduced in the Senate, Referred to Senate Commerce Committee
- Bill type
- bill
- Last updated
- —
Sponsors
- Johnson, Gordon M.primary
Committees
Not provided by source.
Action timeline
2026-05-14
Introduced in the Senate, Referred to Senate Commerce Committee
introduction,referral-committee
Versions
- IntroducedCompare
Documents
Votes
Not provided by source.
Related bills
- Companion bill: A 1510
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:27:43.923511Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NJ&identifier=S 4222. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.